Meg Macy, MD

Professional Titles

• Hoover Family Endowed Chair in Cancer Research and Innovation

Recognitions

• Alpha Omega Alpha Honor Medical Society, Case Western Reserve School of Medicine (2002)
  

Research Interests

Publications

• Macy ME, Lauro C, Zeitler P, Liu A. Primary Hypothryoidism in Pediatric Patients Receiving Craniospinal Irradiation. Poster presentation at the 15th International Symposium on Pediatric Neuro-Oncology. 2012. June 25-27. Toronto Canada
• Hemenway M, Madden J, Macy M, Foreman N, Rush S. Brainstem low grade tumors presenting with BRAF V600E mutation and successful treatment with vemurafenib. Poster presentation at the 15th International Symposium on Pediatric Neuro-Oncology. 2012. June 25-27. Toronto Canada.
• Lauro C, Macy M, Zeitler P, Mettler P, Foreman, Liu A. The Relationship Between Thyroid Dose and Diagnosis of Primary Hypothyroidism in Pediatric Brain Tumor Patients Receiving Craniospinal Irradiation.. Presented at the American Society for Radiation Oncology. October 2012. Boston , MA . Int J Radiat Oncol Biol. Phys. 84(3). S635
• Gore L, Alvaro F, Arndt C, Macy M, Barnette P, Cooper T, Jones M, Martin L, Mechinaud F, Narendran A, Mshinchi JS, Arceci RJ, Boklan J, Tarasoff P, Tcheng W. Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine as an Epigenetic Priming Agent when Combined with Induction Chemotherapy in Pediatric Patients (PTS) with Newly Diagnosed Acute Myelogenous Leukmeia (AML). Presented at the Annual Meeting of the American Society of Hematology. December 2012. Atlanta GA.
• Macy ME, Birks DK, Barton VN, Chan MH, Donson AM, Kleinschmidt-Demasters BK, Bemis LT, Handler MH, Foreman NK. Clinical and molecular characteristics of congenital glioblastoma. Neuro Oncol. 2012 Jul;14(7):931-41. PubMed PMID: 22711608
• May LT, Wang M, Albano E, Garrington T, Dishop M, Macy ME. Undifferentiated sarcoma of the liver: a single institution experience using a uniform treatment approach. J Pediatr Hematol Oncol. 2012 Apr;34(3):e114-6. PubMed PMID: 22217489
• Macy ME, DeRyckere D, Gore L. Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. Invest New Drugs. 2012 Apr;30(2):468-79. PubMed PMID: 21046425
• Macy ME, T Duncan, J Whitlock, SP Hunger, J Boklan, A Narandaren, C Herzog, RJ Arceci, R Bagatell, T Trippett, U Christians, K Rolla, SP Ivy, and L Gore. A Multi-Center Phase 1b Study of Oxaliplatin (NSC#266046) in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors. Pediatric Blood and Cancer. Pediatric Blood and Cancer. 2012 Sept 28 Epub
• Norris R, Shusterman S, Gore L, Macy M, Muscal J, Fox E, Mosse Y, Berkowitz N, Bookbinder A, Bagatell R. Phase I Trial of Polyethylene Glycol (PEG) Conjugated SN38 in Patients (pts) with Recurrent or Refractory Neuroblastoma (NB) and Other Solid Tumors. Poster presentation at the Advances in Neuroblastoma Research. 2012. June 18-21. Toronto Canada.
• Macy M, Kieran M, Chi S, Cohen K, MacDonald T, Smith A, Etzl M, Naranderan A, Gore L, DiRenzo J, Trippett T, Foreman N, Dunkel I. A Phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high grade astrocytomas: a preliminary report from POETIC. Oral presentation at the 15th International Symposium on Pediatric Neuro-Oncology. 2012. June 25-27. Toronto Canada.
• Lauro C, Macy ME, Zeitler P, Backus J, Mettler P, Foreman N, Liu AK. The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation. J Pediatr Endocrinol Metab. 2013 Sep 20;:1-5. [Epub ahead of print] PubMed PMID: 24057590
• Maloney JA, Stence NV, Macy ME, Kleinschmidt-DeMasters BK, and Fenton LZ. A sheep in wolf’s clothing? Radiologic-pathologic correlation and clinical outcome in congenital glioblastoma. Abstract accepted for presentation at the Annual Meeting of the Society of Pediatric Radiology; 2013 May 14-18; San Antonio, TX
• Macy M, Kieran, M, Chi S, Cohen K, MacDonald T, Smith A, Etzl M, Narendran A, Gore L, DiRenzo J, Trippett T, Foreman N, Dunkel I. A Phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high grade astrocytomas. Poster discussion at the 49th Annual Meeting of the American Society of Clinical Oncology. June 2013. Chicago, IL
• Cooper TM, Malvar J, Cassar J, Eckroth E, Sposto R, Gaynon P, DuBois S, Chang B, Gore L, Macy M, August K, Thomson B, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown P. A Phase I Study of AC220 (Quizartinib) in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Oral Presentation at the Annual Meeting of the American Society of Hematology. December 2013. New Orleans, LA
• Kieran M, Yao X, Macy M, Geyer R, Cohen K, MacDonald T, Allen J, Boklan J, Smith A, Nazemi K, Gore L, Trippett T, DiRenzo J, Narendran A, Perentesis J, Prabhu S, Pinches N, Robison N, Manley P, Chi S. A prospective multi-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A POETIC consortium trial. Oral presentation at the 45th Congress of the International Societuy of Paediatric Oncology (SIOP). September 2013. Hong Kong, China
• Bercovitz RS, Macy M, Ambruso DR. A case of autoimmune hemolytic anemia with anti-D specificity in a 1-year-old child. Immunohematology. 2013;29(1):15-8. PubMed PMID: 24046918
• Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. PubMed PMID: 24962521
• Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K, Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. Clin Cancer Res. 2013 Jul 1;19(13):3649-58. PubMed PMID: 23659969
• Lauro C, Macy ME, Zeitler P, Backus J, Mettler P, Foreman N, Liu AK. The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation. J Pediatr Endocrinol Metab. 2014 Mar;27(3-4):299-303. PubMed PMID: 24057590
• Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013 Jun;15(6):783-7. PubMed PMID: 23460318
• 21. Park J, Diede SJ, Fong A, Dubois S, Glade Bender J, Groshen SG, Tsao-Wei D, Ames M, Hass-Kogan D, Macy M, Baruchel S, Reynolds P, Kang M, Marachelian A, Villablanca JG, Matthay KK. A Phase 1 study of Vorinostat in Combination with Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. Oral Presentation at Advances in Neuroblastoma Research. May 2014. Cologne Germany
• 22. Kieran M, Yao X, Macy M, Geyer R, Cohen K, MacDonald T, Allen J, Boklan J, Smith A, Nazemi K, Gore L, Trippett T, DiRenzo J, Narendran A, Perentesis J, Prabhu S, Pinches N, Robison N, Manley P, Chi S. Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A POETIC consortium trial. Oral presentation at the 20th International Conference on Brain Tumor Research and Therapy (ICBRT20) July 2014. Lake Tahoe, CA
• Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L, Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2013 Feb;60(2):230-6. PubMed PMID: 23024067
• Waxweiler TV, Rusthoven CG, Proper MS, Cost CR, Cost NG, Donaldson N, Garrington T, Greffe BS, Heare T, Macy ME, Liu AK. Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A Surveillance, Epidemiology, and End Results Analysis Validating COG Risk Stratifications. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):339-48. PubMed PMID: 25968827
• Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. PubMed PMID: 24962521
• Lauro C, Macy ME, Zeitler P, Backus J, Mettler P, Foreman N, Liu AK. The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation. J Pediatr Endocrinol Metab. 2014 Mar;27(3-4):299-303. PubMed PMID: 24057590
• Waxweiler TV, Rusthoven CG, Proper MS, Cost CR, Cost NG, Donaldson N, Garrington T, Greffe BS, Heare T, Macy ME, Liu AK. Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A Surveillance, Epidemiology, and End Results Analysis Validating COG Risk Stratifications. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):339-48. PubMed PMID: 25968827
• Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 Jul;62:9-17. PubMed PMID: 27185573
• Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017;9:108. PubMed PMID: 29034009
• Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov;64(11). PubMed PMID: 28544128
• Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 2017 Aug;64(8). PubMed PMID: 28409853
• Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 Jul;62:9-17. PubMed PMID: 27185573
• Pacenta HL, Macy ME. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018;12:3549-3561. PubMed PMID: 30425456
• DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. PubMed PMID: 30093449
• Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 Sep;65(9):e27217. PubMed PMID: 29750396
• Moreira DC, Macy ME, Cost CR, Greffe BS, Garrington TP. Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience. J Pediatr Hematol Oncol. 2018 Apr 17. [Epub ahead of print] PubMed PMID: 29668538
• Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 Jul;65(7):e27023. PubMed PMID: 29603591
• Moreira DC, Macy ME, Cost CR, Greffe BS, Garrington TP. Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience. J Pediatr Hematol Oncol. 2019 Mar;41(2):152-154. PubMed PMID: 29668538
• Geoerger B, HJ Kang HJ, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, TW Laetsch, AS Petrilli, M Ebinger, J Toporski, J Glade-Bender, W Nicholls, E Fox, SG DuBois, ME Macy, SL Cohn, K Pathiraja, SJ Diede, S Ebbinghaus, N Pinto. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol, Published online Nov 29, 2019
• Dahl NA, Liu AK, Foreman NK, Widener M, Fenton LZ, Macy ME. Bevacizumab in the treatment of radiation injury for children with central nervous system tumors. Childs Nerv Syst. 2019 Nov;35(11):2043-2046. PubMed PMID: 31367784
• Rossoff J, V Huynh, RE Rau, ME Macy, ML Sulis, KR Schultz, MJ Burke, U Athale, MM O'Brien, JJ Gregory, IM van der Sluis, FG Keller, CM Zwaan, M Suttertorp, N Hijiya. Experience with ponatinib in paediatric patients with leukemia.
• Laetsch TW, DuBois SG, Bender JG, Macy ME, Moreno L. Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov. 2020 Dec 4. [Epub ahead of print] PubMed PMID: 33277309
• Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ Jr, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020 Apr;189(2):363-368. PubMed PMID: 31975387
• Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 Jan;21(1):121-133. PubMed PMID: 31812554
• Dahl NA, Liu AK, Foreman NK, Widener M, Fenton LZ, Macy ME. Bevacizumab in the treatment of radiation injury for children with central nervous system tumors. Childs Nerv Syst. 2019 Nov;35(11):2043-2046. PubMed PMID: 31367784
• Laetsch TW, DuBois SG, Bender JG, Macy ME, Moreno L. Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov. 2021 Mar;11(3):545-559. PubMed PMID: 33277309
• Slatnick LR, Jimeno A, Gore L, Macy ME. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc). 2021 Nov;57(11):677-688. PubMed PMID: 34821881
• Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor Jaclyn Schienda, Alanna J. Church, Laura B. Corson, Brennan Decker, Catherine M. Clinton, Danielle K. Manning, Alma Imamovic-Tuco, Deirdre Reidy, Gianna R. Strand, Mark A. Applebaum, Rochelle Bagatell, Steven G. DuBois, Julia L. Glade-Bender, Wenjun Kang, AeRang Kim, Theodore W. Laetsch, Margaret E. Macy, Luke Maese, Navin Pinto, Amit J. Sabnis, Joshua D. Schiffman, Susan I. Colace, Samuel L. Volchenboum, Daniel A. Weiser, Jonathan A. Nowak, Neal I. Lindeman, Katherine A. Janeway, Brian D. Crompton, and Junne Kamihara JCO Precision Oncology 2021 :5, 1840-1852. Published online December 22, 2021.
• Lerman BJ, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2022 Oct 7;:JCO2201273. [Epub ahead of print] PubMed PMID: 36206505
• Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 Sep 13. [Epub ahead of print] PubMed PMID: 36101004
• Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Aug;28(8):1581-1589. PubMed PMID: 35739269
• DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. PubMed PMID: 35522915
• Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 Nov;6:e2200390. PubMed PMID: 36446043
• Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. PubMed PMID: 35395680
• Loeb DM, Lee JW, Morgenstern DA, Samson Y, Uyttebroeck A, Lyu CJ, Van Damme A, Nysom K, Macy ME, Zorzi AP, Xiong J, Pollert P, Joerg I, Vugmeyster Y, Ruisi M, Kang HJ. Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. Cancer Immunol Immunother. 2022 Oct;71(10):2485-2495. PubMed PMID: 35262780
• Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021;5. PubMed PMID: 34964003
• Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 May;29(5):1092-1102. PubMed PMID: 37012551
• Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 Mar;7:e2200334. PubMed PMID: 36996377
• Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 Nov;6:e2200390. PubMed PMID: 36446043
• Lerman BJ, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 Jan 20;41(3):508-516. PubMed PMID: 36206505
• Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 Nov 1;128(21):3775-3783. PubMed PMID: 36101004
• Morcos PN, Schlender J, Burghaus R, Moss J, Lloyd A, Childs BH, Macy ME, Reid JM, Chung J, Garmann D. Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clin Transl Sci. 2023 Jul;16(7):1197-1209. PubMed PMID: 37042099

Professional Memberships

• American Academy of Pediatrics (AAP), Member
• American Society of Bone Marrow Transplantation, Associate Member
• American Association of Cancer Research , Member
• American Society of Pediatric Hematology/Oncology, Member
• American Society of Hematology, Member

Practice Locations

• Children's Hospital Colorado

Specialty Information

• Pediatric Hematology / Oncology, Board Certification (2008)
• Pediatrics, Board Certification (2005)

• Cancers
• Blood / Lymphatic System - Blood Disorders
• Cancers - Pediatric Cancer
• Blood / Lymphatic System
• Cancers - Cancer Medicine